NYU Langone's mRNA Vaccine Slashes Melanoma Recurrence Risk by 49% in 5-Year Trial

Event summary

  • NYU Langone's phase 2b KEYNOTE-942 trial shows intismeran + pembrolizumab reduces melanoma recurrence risk by 49% over 5 years.
  • 68.8% of combination therapy patients remained cancer-free vs. 49.1% with pembrolizumab alone.
  • Overall survival at 92.2% for combination therapy vs. 71.3% for pembrolizumab alone.
  • Phase 3 trial underway for first-line melanoma therapy; vaccine being tested for lung and other cancers.
  • Study funded by Moderna (intismeran manufacturer) and Merck (pembrolizumab manufacturer).

The big picture

This trial represents a significant validation of personalized mRNA cancer vaccines, potentially expanding the toolkit for treating aggressive tumors. The results come as immunotherapy combinations gain traction in oncology, with checkpoint inhibitors like pembrolizumab becoming foundational treatments. The success of intismeran could accelerate development of neoantigen-targeting vaccines across multiple cancer types, creating new competitive dynamics in the oncology space.

What we're watching

Therapeutic Expansion
Whether intismeran's success in melanoma will translate to other high-mutation cancers like lung.
Regulatory Pathway
The pace at which NYU Langone and Moderna can advance intismeran through phase 3 trials and potential FDA approval.
Commercial Strategy
How Merck and Moderna will position this combination therapy in the competitive melanoma treatment landscape.